MONMOUTH JUNCTION, N.J.,
Aug. 14, 2012 /PRNewswire/
-- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical
company dedicated to the development of innovative inhaled
pharmaceuticals for the treatment of serious lung infections, today
announced that Timothy Whitten,
President and Chief Executive Officer, will be presenting a
corporate overview at the 2012 Wedbush PacGrow Life Sciences
Management Access Conference in New
York on Wednesday, August 15,
2012, at 8:35 AM ET.
A live audio webcast will be made available on Insmed's website,
http://www.insmed.com. The webcast will also be archived for
90 days.
About Insmed
Insmed Incorporated is a biopharmaceutical company dedicated to
the development of innovative inhaled pharmaceuticals for the
treatment of serious lung infections, with a particular focus on
orphan diseases. Insmed's core expertise is the development
of inhaled antibiotic therapy delivered via proprietary advanced
liposomal pulmonary technology. For more information, please
visit http://www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements which are made
pursuant to provisions of Section 21E of the Securities Exchange
Act of 1934. Investors are cautioned that such statements in this
release, including statements relating to our financial position,
our estimates regarding our capital requirements and our needs for
additional financing, our ability to access additional funds under
the Hercules loan agreement, results of operations, the status,
results and timing of results of pre-clinical studies and clinical
trials and pre-clinical and clinical data described herein, the
timing of and costs associated with pre-clinical studies and
clinical trials, the development of our products, our estimates of
the size of the potential markets for our product candidates, and
the business strategies, plans and objectives of management,
constitute forward-looking statements which involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated by the forward-looking statements. Our
results may be affected by such factors as the receipt and timing
of U.S. Food and Drug Administration and other regulatory reviews
and approvals, if at all, competitive developments affecting our
product development, delays in product development or clinical
trials, and patent disputes involving currently developing
products. The risks and uncertainties include, without
limitation, we may experience unexpected regulatory actions, delays
or requests, our future clinical trials may not be successful, we
may be unsuccessful in developing our product candidates or
receiving necessary regulatory approvals, we may experience delays
in our product development or clinical trials, our product
candidates may not prove to be commercially successful, our
expenses may be higher than anticipated, and other risks and
challenges detailed in our filings with the U.S. Securities and
Exchange Commission, including our Annual Report on Form 10-K for
the year ended December 31, 2011 and
our Quarterly Report on Form 10-Q for the quarter ended
June 30, 2012. Investors are
cautioned not to place undue reliance on any forward-looking
statements which speak only as of the date of this release.
We undertake no obligation to publicly release the results of
any revisions to these forward-looking statements that may be made
to reflect events or circumstances that occur after the date of
this release or to reflect the occurrence of unanticipated
events.
Investor Relations Contact:
Brian Ritchie – FTI
Consulting
212-850-5683
brian.ritchie@fticonsulting.com
Media Contact:
Irma Gomez-Dib – FTI Consulting
212-850-5761
irma.gomez-dib@fticonsulting.com
SOURCE Insmed Incorporated